Agenus Inc 뉴스 - AGEN | 주식 나스닥 | ADVFN

다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

Agenus Inc (AGEN)

3.32

-0.13

(-3.77%)

마감 22 2월 6:00AM

3.2187

-0.1013

( -3.05% )

시간외 단일가: 11:07PM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in...

Form 8-K - Current report

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company...

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN...

Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN

Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More...

1
2
다음

Monksdream

Monksdream 2 월 전

Monksdream

Monksdream 4 월 전

Monksdream

Monksdream 6 월 전

AGEN new 52 week low

Monksdream

Monksdream 7 월 전

ErnieBilco

ErnieBilco 7 월 전

I tossed a couple of coins in the fountain at $7 wishing for 50% or better

DP1011

DP1011 8 월 전

Up here. Keep on going!!!

jondoeuk

jondoeuk 10 월 전

I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.

jondoeuk

jondoeuk 11 월 전

The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.

jondoeuk

jondoeuk 11 월 전

They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html

Paullee

Paullee 1 년 전

where did you see that ??????

TrendTrade2016

TrendTrade2016 1 년 전

ALL OUT...REVERSE SPLIT ANNOUNCEMENT

TrendTrade2016

TrendTrade2016 1 년 전

AGEN SMALL GAPPER AND ON TARGET TO 1.04

DP1011

DP1011 1 년 전

Interesting, would be nice to see this back over a dollar.

Stumblebum

Stumblebum 1 년 전

Something is cooking …..last week good upward movement and picked up volume 😊

TrendTrade2016

TrendTrade2016 1 년 전

AGEN POPPING HARD TO 1.04

axelvento

axelvento 1 년 전

A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$

Denzel-72

Denzel-72 1 년 전

R/S is coming … money down the drain

Monksdream

Monksdream 1 년 전

AGEN new 52 week low

TommyBoyTrader9460

TommyBoyTrader9460 1 년 전

$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61

TommyBoyTrader9460

TommyBoyTrader9460 1 년 전

$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61

Doktornolittle

Doktornolittle 1 년 전

Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.

Monksdream

Monksdream 1 년 전

AGEN new 52 week low

Monksdream

Monksdream 1 년 전

AGEN new 52 week low

Monksdream

Monksdream 1 년 전

AGEN new 52 week low

Monksdream

Monksdream 1 년 전

AGEN new 52 week low

Doktornolittle

Doktornolittle 2 년 전

... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.

Doktornolittle

Doktornolittle 2 년 전

B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.

Doktornolittle

Doktornolittle 2 년 전

SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.

stockguard

stockguard 3 년 전

AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.

north40000

north40000 3 년 전

$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.

investtemp

investtemp 3 년 전

what was the B Riley target price?

stockguard

stockguard 3 년 전

B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.

stockguard

stockguard 3 년 전

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html

stockguard

stockguard 3 년 전

Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s

pipette

pipette 3 년 전

There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.

malice1

malice1 3 년 전

China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?

Jnk

stockguard

stockguard 3 년 전

Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.

Jnk

Well I just bought a bunch more shares!! Hope it pays out!!

stockguard

stockguard 3 년 전

UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes

stockguard

stockguard 3 년 전

Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/

malice1

malice1 3 년 전

longboarder have any idea what happened the last two days?

longboarder7892

longboarder7892 3 년 전

Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

conix

conix 4 년 전

ClayTrader

ClayTrader 4 년 전

* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

JohnLocke101

JohnLocke101 4 년 전

Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+

iancnyc

iancnyc 4 년 전

thank god i heard on
look at that!!!

moonurneighbor

moonurneighbor 4 년 전

JohnLocke101

JohnLocke101 4 년 전

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

iancnyc

iancnyc 4 년 전

what’s going on with this Turd today?

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관